IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 03, 2014
Proove Biosciences, the commercial and research leader in personalized medicine, will be exhibiting data and research conducted through their latest proprietary testing services at this year’s PAINWeek, the nation’s largest pain conference for clinicians in pain management. This year’s conference is taking place this week at The Cosmopolitan of Las Vegas.
PAINWeek offers a multidisciplinary faculty and diverse curriculum in several pain concentrations including behavioral pain management, diabetes and pain, interventional pain management, chemical dependency and pharmacotherapy. Over 1,800 physicians, physician assistants, nurse practitioners, pharmacists, and social workers are expected to attend this year.
“PAINWeek is the industry’s leading conference dedicated to promoting the latest and most ground breaking science and treatment options for pain from all sources,” stated Proove Biosciences CEO, Brian Meshkin. “Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain.”
Major components of this year’s forum will be emerging and alternative technologies in interventional pain management, and how genetics and gender play a vital role patient pain and pain management.
“We are looking forward to exhibiting three posters of data, and explaining how our research is helping patients better manage and understand their pain, while lowering the associated healthcare costs and increasing prescription efficiency. Proove researcher and team member, Dr. Derrick Holman will be present at the conference to illustrate how Proove’s science is helping physicians realize the promise of personalized medicine.”
About Proove Biosciences
Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.
Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).